Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04436640 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
A Phase 3 study of Ankylosing Spondylitis and Axial Spondyloarthritis, sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 508
- Enrollment target
- 20
- Study locations
NCT04436640 is a Phase 3 study of Ankylosing Spondylitis and Axial Spondyloarthritis that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 508 participants, below the 38,163-participant average among 15 other Ankylosing Spondylitis trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04436640, a Phase 3 study of Ankylosing Spondylitis and Axial Spondyloarthritis, is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 508 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
Conditions Studied
Interventions
- DRUG Bimekizumab
Study Locations (20)
Other
- As0014 40004 - Brussels
- As0014 40003 - Genk
- As0014 40001 - Ghent
- As0014 40006 - Plovdiv
- As0014 40007 - Plovdiv
- As0014 40005 - Sofia
- As0014 40008 - Sofia
- As0014 20040 - Beijing
- As0014 20021 - Chengdu
- As0014 20019 - Guangzhou
Arizona
- As0014 50062 - Glendale
- As0014 50052 - Phoenix
Florida
- As0014 50059 - Ormond Beach
- As0014 50056 - Sarasota
California
- As0014 50060 - Upland
Maryland
- As0014 50015 - Hagerstown
Missouri
- As0014 50016 - St Louis
Oregon
- As0014 50055 - Portland
Pennsylvania
- As0014 50020 - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2020-06-16 |
| Est. Completion | 2026-08-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04436640
The ClinicalTrials.gov registry entry for NCT04436640 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38,163-participant average among 15 other Ankylosing Spondylitis trials with a reported enrollment target (99% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ankylosing Spondylitis appearing as the primary indexed condition, and to 1 intervention - of which Bimekizumab is the first listed.
NCT04436640 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT04436640 about?
NCT04436640 is a clinical study titled "A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis". The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
What is the current status of trial NCT04436640?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 508 participants. The study started on 2020-06-16. Estimated completion is 2026-08-07.
What conditions does trial NCT04436640 study?
This clinical trial studies the following conditions: Ankylosing Spondylitis, Axial Spondyloarthritis, r-axSpa, Nr-axSpa.
What interventions are being tested in trial NCT04436640?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT04436640?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04436640 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ankylosing Spondylitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
COMPLETED · Phase 3
-
Rheumatology Diet Study
RECRUITING
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Rheumatology Patient Registry and Biorepository
RECRUITING
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
-
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.